Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 4
Abstract
Introduction and aim. Studies suggest that entecavir and lamivudine are useful as prophylactics against hepatitis B virus (HBV) reactivation in patients undergoing chemotherapy or immunosuppressive therapy, but which drug is more effective is unclear. Here we meta-analyzed available evidence on relative efficacy of prophylactic entecavir or lamivudine therapy in patients with chronic or resolved hepatitis B infection who were undergoing chemotherapy or immunosuppressive therapy. Material and methods. Two reviewers searched PubMed, EMBASE and Google Scholar as well as reference lists in relevant articles to find studies published between January 2005 and May 2015 that met inclusion and exclusion criteria. Data on HBV reactivation, HBV-related hepatitis and all-cause mortality were extracted from the studies and meta-analyzed. Results. A total of eight studies involving 593 patients were included in the meta-analysis, which was performed using a fixed-effect model since no significant heterogeneity was found. Entecavir was associated with significantly lower risk of HBV reactivation than lamivudine (RR 0.29, 95% CI 0.17 to 0.52) as well as lower risk of HBV-related hepatitis (RR 0.11, 95% CI 0.03 to 0.40). The two drugs were associated with similar risk of all-cause mortality (RR 1.12, 95% CI 0.54 to 2.35). Egger’s test suggested no significant publication bias in the meta-analysis. Conclusions. The available evidence suggests that entecavir is more effective than lamivudine for preventing HBV reactivation and HBVrelated hepatitis in patients with chronic or resolved HBV infection who are undergoing chemotherapy or immunosuppressive therapy.
Authors and Affiliations
Chun Yang, Bo Qin, Zhe Yuan, Limin Chen, Hong-yu Zhou
Keywords
Related Articles
- EP ID EP78594
- DOI 10.5604/16652681.1202910
- Views 134
- Downloads 0
PGE2 induces MUC2 and MUC5AC expression in human intrahepatic biliary epithelial cells via EP4/p38MAPK activat
[b]Background[/b]. MUC2 and MUC5AC overproduction is considered to be associated with hepatolithiasis and related to inflammation. However, mechanisms underlying MUC upregulation under inflammatory stimulation in human i...
Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects
Introduction. CYP2D6 is a liver enzyme that metabolizes more that 25% of drugs and thus may play a pivotal role in drug-drug interactions. The promoter sequences of cytochrome P450 2D6 (CYP2D6) gene could impact metaboli...
Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes
Background. The information available on time and dose effects of the exposure of hepatocytes to free fatty acids (FFA) in vitro is controversial, and very few studies have assessed the hepatocyte inflammatory response i...
Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients
Background. Conflicting data have been reported on the prevalence of liver steatosis, its risk factors and its relationship with fibrosis in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-inf...
Prevalence of hepatitis A, B and C serological markers in children from western Mexico
Introduction. Viral hepatitis in children is a major public health problem worldwide. Aim. To evaluate the prevalence of serological markers for hepatitis A, B and C infections in Mexican children diagnosed with hepatiti...